An In Vitro Pharmacognostical Study on Gluconeogenesis and Glucose

Traditional medicine over 60% of the world’s population used for health care name as Mukia maderaspatana (L.) M. Roem. (Cucurbitaceae) (Mukia) is extensively important medicine as an anti-inflammatory plant. It is rich in content of phenolics that exerts various medicinal properties. Mukia extract and its derivatives phenolics such as quercetin and phloroglucinol are investigated for their in vitro anti-inflammatory activity. Materials used was Quercetin, phloroglucinol, and methanol which extract of the dried whole plant (0.55 and 0.6 mg/ml) were studied for the inhibition of gluconeogenesis and glucose Phenolics of Mukia were analyzed by HPLC and UV-spectroscopy. Results obtained were Glucose (1.5 mg/g/h) was synthesized from pyruvate, the synthesis was whole inhibited by insulin (1 U/ml). Quercetin at 0.35 and 0.6 mg/ml caused 60% and 90% inhibition (0.43 mg/g/h and 0.12 mg/g/h glucose). Addition of insulin did not increase inhibition. Phloroglucinol inhibited 100% glucose production with or without insulin. Mukia (0.20 mg/ml) inhibited gluconeogenesis (0.65 mg/g/h) by 40%, and with insulin, inhibition increased to 50% (0.59 mg/g/h). At 0.6 mg/ml, glucose synthesis was stimulated by1.3-fold, but with insulin gets inhibited by 90% (0.12 mg/g/h glucose). Mukia possessed no effect on glucose uptake, in case it potentiated the activity of insulin mediated glucose uptake (153.82 ± 12.30 mg/dl/g/30 min) compared with insulin control (122.41 ± 9.14 mg/dl/g/30 min) (p < 0.02). HPLC analysis revealed the presence of phenolics. Results were concluded scientific rationale for the use of Mukia in medicine as an anti-inflammatory nutraceutical.